Keyphrases
Remission
100%
Young Patients
100%
Consolidation Therapy
100%
Initial Treatment
100%
Mantle Cell Lymphoma
100%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Rituximab
100%
B-cell Malignancies
50%
Overall Survival
50%
Maintenance Therapy
50%
Patient Well-being
50%
Treatment Strategy
50%
Novel Agents
50%
Long-term Treatment
50%
Time to Relapse
50%
High-dose Chemotherapy
50%
Immunochemotherapy
50%
Late Relapse
50%
High-dose Cytarabine
50%
Medicine and Dentistry
Mantle Cell Lymphoma
100%
Rituximab
100%
Autologous Stem Cell Transplantation
100%
B Cell
50%
Cancer
50%
Overall Survival
50%
Cytarabine
50%
Drug Megadose
50%
Quality of Life
50%
Maintenance Therapy
50%
High Dose Chemotherapy
50%